Insulin Detemir

證據等級: L5

預測適應症: 10 個

Insulin Detemir: From an Undocumented Original Indication to Type 1 Diabetes Mellitus (Likely Existing-Use Case)

One-Sentence Summary

Insulin detemir’s original indication is not recorded in this evidence pack (data gap), but the drug is generically known as a long-acting basal insulin analogue. The TxGNN model predicts it may be effective for Type 1 Diabetes Mellitus, with dozens of clinical trials (many completed Phase 3 RCTs) and substantial literature currently supporting this direction — however, this is very likely an already-approved existing indication rather than a genuinely novel repurposing signal, and this must be verified before any “new indication” claim is made.

Quick Overview

Item	Content
Original Indication	Not recorded in this dataset — insulin detemir is generically a long-acting basal insulin, so this is likely an existing (not new) indication; requires verification
Predicted New Indication	Type 1 Diabetes Mellitus
TxGNN Prediction Score	99.77%
Evidence Level	L1
Denmark Market Status	Not Marketed (per this dataset — see caveat below)
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (data gap DG002, severity: High). Generically, insulin detemir is a recombinant human insulin analogue modified at the B29 lysine residue with a C14 (myristic acid) fatty-acid chain, which allows reversible binding to serum albumin. This slows subcutaneous absorption and produces a protracted, relatively flat time-action profile compared with NPH insulin — the pharmacological basis for its use as a once- or twice-daily basal insulin. This is the same active substance marketed internationally under the brand name Levemir®.

Because the original_indications field in this dataset is empty, the system could not automatically confirm whether “type 1 diabetes mellitus” is already the drug’s approved indication rather than a novel one. Long-acting basal insulin analogues of this class are, by design and by regulatory history, indicated for basal glycaemic control in both type 1 and type 2 diabetes. The extremely high TxGNN score (99.77%) combined with a very large body of completed Phase 3 randomised controlled trials most plausibly reflects a strong, already-established drug–disease relationship in the knowledge graph — not a novel mechanistic hypothesis.

The evidence pack’s own repurposing rationale flags this directly: “此案例的決策重點在於『引進/上市可行性』而非機轉新穎性…建議人工核實後移除或標註為『既有適應症之市場引進』而非典型 repurposing 候選” (the decision focus here is market-entry feasibility, not mechanistic novelty; human review should reclassify this as “market introduction of an existing indication” rather than a typical repurposing candidate). This caveat should be resolved — by retrieving the drug’s documented original indication from TFDA/DrugBank/SmPC — before this candidate is treated as a genuine old-drug-new-use opportunity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03220425	Phase 3	Completed	752	6-month efficacy/safety comparison of insulin detemir vs NPH insulin in T1DM basal-bolus regimen; large direct evidence base
NCT01486940	Phase 3	Completed	598	Multinational RCT comparing detemir+aspart vs NPH+human soluble insulin in T1DM basal-bolus therapy
NCT01513473	Phase 3	Completed	350	BEGIN™ Young 1: 26-week (+26-week extension) comparison of insulin degludec vs detemir in children/adolescents with T1DM
NCT00447382	Phase 3	Completed	330	12-month double-blind safety comparison of two detemir manufacturing processes in T1DM basal-bolus regimen
NCT01709929	Phase 3	Completed	2287	Large multicentre, non-randomised safety study of insulin detemir in T1DM and T2DM
NCT01461616	Phase 3	Completed	19	Open-label triple crossover trial comparing NPH, detemir and glargine on IGFBP-1/IGF-I in T1DM
NCT00738153	N/A (observational)	Completed	798	Observational study (Africa) evaluating efficacy and serious ADR incidence with Levemir® in T1DM and T2DM
NCT00687284	N/A (observational)	Completed	2188	Large European observational study of glycaemic control with Levemir® as initiation therapy
NCT01271517	Phase 4	Unknown	120	RCT in newly diagnosed adolescents comparing NPH, glargine and detemir on metabolic control and GH/IGF-I axis
NCT00595374	Phase 3	Completed	114	European RCT comparing detemir+aspart vs NPH+aspart in adults with T1DM

Note: dozens of additional Phase 1–4 trials (both RCTs and observational studies) exist in the evidence pack beyond this top-10 selection; the full set spans pregnancy, paediatric, and comparator (glargine/degludec) populations.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36623517	2023	RCT	Lancet Diabetes Endocrinol	EXPECT trial: open-label, multinational non-inferiority RCT of degludec vs detemir (both + aspart) in pregnant women with T1DM
36763996	2022	Systematic review/Meta-analysis	Clin Ther	Efficacy/tolerability of degludec vs other long-acting basal analogues (incl. detemir) in T1DM/T2DM
29477399	2018	Systematic review/Network meta-analysis	Value Health	Comparative efficacy and safety of basal insulin regimens in adults with T1DM
23110609	2012	Review	Drugs	Comprehensive review of insulin detemir’s role as basal therapy in T1DM and T2DM
21878861	2011	Systematic review/Meta-analysis	Pol Arch Med Wewn	Detemir vs NPH insulin in T1DM — glycaemic control outcomes
17326333	2006	Review	Vasc Health Risk Manag	Mechanism and clinical use of detemir in T1DM and T2DM, including reduced hypoglycaemia risk
15516157	2004	Review	Drugs	Early comprehensive review of detemir’s pharmacology and use in T1DM/T2DM
20539842	2010	Review	Vasc Health Risk Manag	Updated treatment review positioning detemir among basal insulin analogues
36896906	2024	Review	Curr Diabetes Rev	Two-decade review of glargine in T1DM, with detemir as a key comparator
18454569	2008	Review	Paediatr Drugs	Review of insulin analogue preparations, including detemir, in children/adolescents with T1DM

Denmark Market Information

No marketing authorisations for insulin detemir are recorded in this dataset (market status: Not Marketed, 0 licenses on file).

Important caveat: Insulin detemir (Levemir®) is an internationally marketed, EMA centrally-authorised product. A “0 licenses / not marketed” result in this evidence pack is inconsistent with its known global regulatory status and should be treated as a probable data gap rather than confirmation of true absence from the Danish market. This must be verified directly against the Laegemiddelstyrelsen register and the EMA centralised procedure database before any market-entry decision is finalised.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Critical outstanding gap: TFDA/SmPC label warnings and contraindications could not be retrieved for this evaluation (data gap DG001, severity: Blocking). Per the evidence pack, this gap means the candidate cannot proceed to the S1 safety initial-assessment stage until label data is obtained. This alone is sufficient reason to hold the case regardless of the strength of the efficacy evidence above.

Conclusion and Next Steps

Decision: Hold

Rationale:

A Blocking-severity data gap (missing TFDA/SmPC warnings and contraindications) prevents any safety initial assessment (S1), independent of how strong the efficacy evidence is.
The predicted “new” indication (type 1 diabetes mellitus) is very likely an already-approved, existing use of insulin detemir rather than a genuine repurposing candidate; the case should be reclassified once the drug’s documented original indication is confirmed.
Separately, the model’s other predictions for this drug (autoimmune oophoritis, opsismodysplasia, thiamine-responsive dysfunction syndrome, classic/focal stiff person syndrome) are all Evidence Level L5 with no supporting trials or literature, and are already correctly flagged “Hold” — these most likely reflect indirect knowledge-graph paths (shared autoimmune/comorbidity or insulin-signalling nodes) rather than plausible clinical hypotheses.

To proceed, the following is needed:

Retrieve TFDA/Laegemiddelstyrelsen SmPC label (warnings, contraindications) to close the Blocking data gap and enable S1 safety assessment
Retrieve confirmed mechanism-of-action and original approved indication(s) from DrugBank/regulatory sources to determine whether “type 1 diabetes mellitus” is genuinely novel or an existing use
Verify actual Danish/EU marketing authorisation status for insulin detemir (Levemir®), since “0 licenses / not marketed” appears inconsistent with its known EMA-centralised approval
If reclassified as an existing indication, redirect this evidence pack toward a market-access/pricing review rather than a repurposing evaluation
If any of the lower-ranked rare-disease predictions are of separate interest, commission targeted literature/mechanistic searches before further action, as none currently have any supporting evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.